SPOTLIGHT -
Educating Infusion Nurses on Infection Risks of Anti-BCMA Bispecific Antibodies in MM Treatment
Experts discuss how they educate infusion nurses and other colleagues treating patients with multiple myeloma on the infection risks of BCMA-targeting bispecific antibodies.
Patient Case 3: A 79-Year-Old Female With IgG Kappa Multiple Myeloma
Registered Nurse Annel Urena presents the case of a 79-year-old female with IgG Kappa multiple myeloma and five previous lines of therapy.
Patient Case 2: A 74-Year-Old Male With Kappa LC Multiple Myeloma
Nurse Practitioner Kiah Purcell presents a case of a 74-year-old male with kappa light chain myeloma after ten lines of therapy.
Patient Case 1: A 69-Year-Old Male With Relapse/Refractory IgG Lambda Multiple Myeloma
Annel Urena, RN, BSN, presents the case of a 69-year-old male with relapsed refractory IgG Lambda multiple myeloma after six lines of therapy.
Infection Patterns of Bispecific Antibodies in Multiple Myeloma Treatment
Robert Mancini, PharmD, and Kiah Purcell, AGPCNP-B, discuss other targets for bispecific antibodies in multiple myeloma treatment and the infection patterns.
Overview of Bispecific Antibodies in Multiple Myeloma Treatment
Dr Robert Mancini summarizes the role of BCMA-targeted bispecific antibodies in multiple myeloma treatment and the side effects usually seen.
